MedAvail Holdings 관리

관리 기준 확인 1/4

MedAvail Holdings CEO는 Mark Doerr, Jan2022 에 임명되었습니다 의 임기는 2.08 년입니다. 총 연간 보상은 $ 2.52M, 16.8% 로 구성됩니다. 16.8% 급여 및 83.2% 보너스(회사 주식 및 옵션 포함). 는 $ 6.79K 가치에 해당하는 회사 주식의 0.23% 직접 소유합니다. 6.79K. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 2.7 년입니다.

주요 정보

Mark Doerr

최고 경영자

US$2.5m

총 보상

CEO 급여 비율	16.8%
CEO 임기	2.1yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	2.7yrs

최근 관리 업데이트

Recent updates

Slammed 31% MedAvail Holdings, Inc. (NASDAQ:MDVL) Screens Well Here But There Might Be A Catch

Aug 17

Is There An Opportunity With MedAvail Holdings, Inc's (NASDAQ:MDVL) 32% Undervaluation?

Feb 20

CEO 보상 분석

Mark Doerr 의 보수는 MedAvail Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2023	n/a	n/a	-US$54m
Mar 31 2023	n/a	n/a	-US$55m
Dec 31 2022	US$3m	US$424k	-US$48m

보상 대 시장: Mark 의 총 보상 ($USD 2.52M )은 US 시장( $USD 652.28K ).

보상과 수익: Mark 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Mark Doerr (53 yo)

2.1yrs

테뉴어

US$2,524,419

보상

Mr. Mark Doerr, RPh serves as Chief Executive Officer, President and Director at MedAvail Holdings, Inc since January 10, 2022. He serves as the Chief Executive Officer of eRx Network, LLC since March 28,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mark Doerr	CEO, President & Director	2.1yrs	US$2.52m	0.23% $ 6.8k
Ramona Seabaugh	CFO, Treasurer & Secretary	2.4yrs	US$537.22k	0.076% $ 2.2k
Emilia Keric	Senior VP & General Counsel	less than a year	데이터 없음	데이터 없음
Joan O'Rourke	President of SpotRx	2.8yrs	데이터 없음	데이터 없음
Brian Schlerf	Corporate Controller	3.1yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

경험이 풍부한 관리: MDVL 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mark Doerr	CEO, President & Director	2.1yrs	US$2.52m	0.23% $ 6.8k
Robert Faulkner	Chairman of the Board	3.3yrs	데이터 없음	0.12% $ 3.6k
Laurie McGraw	Independent Director	2.1yrs	US$217.96k	0% $ 0
Michael Kramer	Independent Director	3.3yrs	US$187.00k	0% $ 0
Glen Stettin	Independent Director	3.3yrs	US$170.00k	0% $ 0
Paul Johnson	Independent Director	2.1yrs	US$224.96k	0% $ 0

2.7yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: MDVL 의 이사회는 경험(평균 재직 기간 2.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

MedAvail Holdings 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

MedAvail Holdings, Inc. Announces Board of Directors Resignations

High number of new and inexperienced directors

High number of new and inexperienced directors

Medavail Holdings, Inc. Announces Executive Resignations

High number of new and inexperienced directors

MedAvail Holdings, Inc., Annual General Meeting, Jun 14, 2022

Recent updates

MedAvail Holdings, Inc.(OTCPK:MDVL.Q) dropped from S&P TMI Index

MedAvail Holdings, Inc.(OTCPK:MDVL.Q) dropped from NASDAQ Composite Index

Nasdaq to Delist Common Stock of MedAvail Holdings

MedAvail Holdings, Inc. Filed for Bankruptcy

MedAvail Holdings, Inc. Announces Board of Directors Resignations

MedAvail Holdings, Inc. announced delayed 10-Q filing

Slammed 31% MedAvail Holdings, Inc. (NASDAQ:MDVL) Screens Well Here But There Might Be A Catch

High number of new and inexperienced directors

MedAvail Announces 1-for-50 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

MedAvail Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2023

MedAvail Holdings, Inc. announced delayed 10-Q filing

Full year 2022 earnings: EPS exceeds analyst expectations

High number of new and inexperienced directors

Medavail Holdings, Inc. Announces Executive Resignations

German Dobson CVS, L.L.C., Garfield Beach CVS, L.L.C., Holiday CVS, L.L.C., Longs Drug Stores California, Inc. and Woodward Detroit CVS, L.L.C. entered into the asset purchase and sale agreement to acquire Pharmacy Assets of MedAvail Holdings, Inc. for $4.4 million.

Medavail Holdings, Inc. Initiates Reduction in Force

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MedAvail Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

MedAvail Holdings Receives A Letter from Nasdaq Regarding Minimum Bid Price Requirement

MedAvail Holdings, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus estimates of losses per share improve by 31%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

MedAvail Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

MedAvail Holdings: More Stock Dilution Seems Inevitable And I'm Bearish

MedAvail Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

MedAvail Holdings, Inc.(NasdaqCM:MDVL) dropped from Russell 2000 Growth Index

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

MedAvail Holdings, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$5.00

Less than half of directors are independent

Consensus estimates of losses per share improve by 22%

Price target increased to US$8.00

MedAvail Holdings, Inc announced that it expects to receive $50.04375 million in funding

Medavail Holdings, Inc Strengthens Leadership Team

MedAvail Holdings, Inc Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

Price target decreased to US$7.50

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.74 loss in 3Q 2020)

Consensus revenue estimates fall to US$21.1m

Some Analysts Just Cut Their MedAvail Holdings, Inc (NASDAQ:MDVL) Estimates

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$4.11 loss in 2Q 2020)

Medavail Holdings, Inc Revises Revenue Guidance for the Full Year 2021

Calculating The Intrinsic Value Of MedAvail Holdings, Inc (NASDAQ:MDVL)

MedAvail Holdings, Inc Narrows Revenue Guidance for the Full Year of Fiscal 2021

Full year 2020 earnings released: US$0.84 loss per share (vs US$16.85 loss in FY 2019)

MedAvail Holdings, Inc to Report Q4, 2020 Results on Mar 30, 2021

Is There An Opportunity With MedAvail Holdings, Inc's (NASDAQ:MDVL) 32% Undervaluation?

MedAvail’s SpotRx Pharmacy and Cigna Medical Group Partner to Help Improve Medication Access in Phoenix

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령